Search Results - "GREILLIER, Laurent"

The clinical utility of tumor mutational burden in non-small cell lung cancer by Greillier, Laurent, Tomasini, Pascale, Barlesi, Fabrice

“…Despite advances made during the last two decades, lung cancer remains the leading cause of cancer-related death worldwide. Recently, immune checkpoint…”
Get full text

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial by Zalcman, Gérard, Prof, Mazieres, Julien, Prof, Margery, Jacques, MD, Greillier, Laurent, MD, Audigier-Valette, Clarisse, MD, Moro-Sibilot, Denis, Prof, Molinier, Olivier, MD, Corre, Romain, MD, Monnet, Isabelle, MD, Gounant, Valérie, MD, Rivière, Frédéric, MD, Janicot, Henri, MD, Gervais, Radj, MD, Locher, Chrystèle, MD, Milleron, Bernard, MD, Tran, Quan, MSc, Lebitasy, Marie-Paule, MD, Morin, Franck, MSc, Creveuil, Christian, PhD, Parienti, Jean-Jacques, Prof, Scherpereel, Arnaud, Prof

“…Summary Background Malignant pleural mesothelioma is an aggressive cancer with poor prognosis, linked to occupational asbestos exposure. Vascular endothelial…”
Get full text

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 by Owonikoko, Taofeek K, Park, Keunchil, Govindan, Ramaswamy, Ready, Neal, Reck, Martin, Peters, Solange, Dakhil, Shaker R, Navarro, Alejandro, Rodríguez-Cid, Jerónimo, Schenker, Michael, Lee, Jong-Seok, Gutierrez, Vanesa, Percent, Ivor, Morgensztern, Daniel, Barrios, Carlos H, Greillier, Laurent, Baka, Sofia, Patel, Miten, Lin, Wen Hong, Selvaggi, Giovanni, Baudelet, Christine, Baden, Jonathan, Pandya, Dimple, Doshi, Parul, Kim, Hye Ryun

“…In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability…”
Get full text

Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non–small-cell Lung Cancer by Grangeon, Mathieu, Tomasini, Pascale, Chaleat, Solene, Jeanson, Arnaud, Souquet-Bressand, Maxime, Khobta, Nataliya, Bermudez, Julien, Trigui, Youssef, Greillier, Laurent, Blanchon, Marilyne, Boucekine, Mohamed, Mascaux, Celine, Barlesi, Fabrice

“…Immune checkpoint inhibitors (ICIs) are available for first- and further lines of treatment of patients with advanced non–small-cell lung cancer (NSCLC). These…”
Get full text

Real-life clinical management patterns in extensive-stage small cell lung cancer across France: a multi-method study by Mennecier, Bertrand, Khalifa, Jonathan, Descourt, Renaud, Greillier, Laurent, Naltet, Charles, Falchero, Lionel

“…We designed this study based on both a physician practice survey and real-world patient data to: (1) evaluate clinical management practices in extensive-stage…”
Get full text

Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases by Tomasini, Pascale, Egea, Julie, Souquet-Bressand, Maxime, Greillier, Laurent, Barlesi, Fabrice

“…Molecular profiling of metastatic nonsquamous non-small cell lung cancer (NSCLC) is required to guide the treatment strategy. Anaplastic lymphoma kinase (ALK)…”
Get full text

Immune Oncology Biomarkers in Lung Cancer: an Overview by Travert, Camille, Barlesi, Fabrice, Greillier, Laurent, Tomasini, Pascale

“…Purpose of Review Lung cancer is still the first cause of cancer-related deaths worldwide. The development of immune checkpoint inhibitors (ICI) has…”
Get full text

Personalised medicine for nonsmall cell lung cancer by Mascaux, Céline, Tomasini, Pascale, Greillier, Laurent, Barlesi, Fabrice

“…After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision…”
Get full text

Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes by Tomasini, Pascale, Barlesi, Fabrice, Mascaux, Celine, Greillier, Laurent

“…Non-small cell lung cancer (NSCLC) is still the leading cause of cancer-related death, and the treatment of advanced NSCLC relies on systemic treatments…”
Get full text

ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma by Opitz, Isabelle, Scherpereel, Arnaud, Berghmans, Thierry, Psallidas, Ioannis, Glatzer, Markus, Rigau, David, Astoul, Philippe, Bölükbas, Servet, Boyd, Jeanette, Coolen, Johan, De Bondt, Charlotte, De Ruysscher, Dirk, Durieux, Valerie, Faivre-Finn, Corinne, Fennell, Dean A, Galateau-Salle, Francoise, Greillier, Laurent, Hoda, Mir Ali, Klepetko, Walter, Lacourt, Aude, McElnay, Phil, Maskell, Nick A, Mutti, Luciano, Pairon, Jean-Claude, Van Schil, Paul, van Meerbeeck, Jan P, Waller, David, Weder, Walter, Putora, Paul Martin, Cardillo, Giuseppe

“…Abstract The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European…”
Get full text

EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease by Levy, Antonin, Hendriks, Lizza E.L., Berghmans, Thierry, Faivre-Finn, Corinne, GiajLevra, Matteo, GiajLevra, Niccolò, Hasan, Baktiar, Pochesci, Alessia, Girard, Nicolas, Greillier, Laurent, Lantuéjoul, Sylvie, Edwards, John, O'Brien, Mary, Reck, Martin, Besse, Benjamin, Novello, Silvia, Dingemans, Anne-Marie C.

“…Synchronous oligometastatic disease (sOM) has been described as a distinct disease entity; however, there is no consensus on OM definition (OM-d) in…”
Get full text

Functional status in older patients with lung cancer: an observational cohort study by Couderc, Anne-Laure, Tomasini, Pascale, Greillier, Laurent, Nouguerède, Emilie, Rey, Dominique, Montegut, Coline, Thomas, Pascal-Alexandre, Barlesi, Fabrice, Villani, Patrick

“…Purpose An assessment of the impact of functional status (FS) evaluated using a combination of Activities of Daily Living (ADL) and the short version of the…”
Get full text

Killing a fly with a sledgehammer: Atezolizumab exposure in real‐world lung cancer patients by Marolleau, Sophie, Mogenet, Alice, Boeri, Clara, Hamimed, Mourad, Ciccolini, Joseph, Greillier, Laurent

“…Atezolizumab is an anti‐PDL1 approved for treating lung cancer. A threshold of 6 μg/mL in plasma has been associated with target engagement. The extent to…”
Get full text

EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer by Tomasini, Pascale, Serdjebi, Cindy, Khobta, Nataliya, Metellus, Philippe, Ouafik, L'Houcine, Nanni, Isabelle, Greillier, Laurent, Loundou, Anderson, Fina, Frederic, Mascaux, Celine, Barlesi, Fabrice

“…Lung cancer is the leading cause of brain metastases (BM). The identification of driver oncogenes and matched targeted therapies has improved outcome in…”
Get full text

Comparison between Immunocytochemistry, FISH and NGS for ALK and ROS1 Rearrangement Detection in Cytological Samples by Frankel, Diane, Nanni, Isabelle, Ouafik, L’Houcine, Camilla, Clara, Pellegrino, Eric, Beaufils, Nathalie, Greillier, Laurent, Dutau, Hervé, Astoul, Philippe, Kaspi, Elise, Roll, Patrice

“…The detection of ROS1 and ALK rearrangements is performed for advanced-stage non-small cell lung cancer. Several techniques can be used on cytological samples,…”
Get full text

Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer by Mogenet, Alice, Finetti, Pascal, Denicolai, Emilie, Greillier, Laurent, Boudou-Rouquette, Pascaline, Goldwasser, François, Lumet, Gwenael, Ceccarelli, Michele, Birnbaum, Daniel, Bedognetti, Davide, Mamessier, Emilie, Barlesi, Fabrice, Bertucci, François, Tomasini, Pascale

“…Background Anti-PD1/PDL1 immune checkpoint inhibitors (ICI) transformed the prognosis of patients with advanced non-small cell lung cancer (NSCLC). However,…”
Get full text

Outcomes of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with the Upfront Single Agent Pembrolizumab: A Retrospective and Multicentric Study of the ESCKEYP GFPC Cohort by Nannini, Simon, Guisier, Florian, Curcio, Hubert, Ricordel, Charles, Demontrond, Pierre, Abdallahoui, Safa, Baloglu, Seyyid, Greillier, Laurent, Chouaid, Christos, Schott, Roland

“…Non-small cell lung cancer (NSCLC) is the most common cause of brain metastasis (BM). Little is known about immune checkpoint inhibitor activity in the central…”
Get full text

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience by Greillier, Laurent, Tomasini, Pascale, Barlesi, Fabrice

“…Angiogenesis is one of the hallmarks of cancer. Antivascular endothelial growth factor therapy, including bevacizumab, is therefore a major option in targeting…”
Get full text

MST1/Hippo promoter gene methylation predicts poor survival in patients with malignant pleural mesothelioma in the IFCT-GFPC-0701 MAPS Phase 3 trial by Maille, Elodie, Brosseau, Solenn, Hanoux, Vincent, Creveuil, Christian, Danel, Claire, Bergot, Emmanuel, Scherpereel, Arnaud, Mazières, Julien, Margery, Jacques, Greillier, Laurent, Audigier-Valette, Clarisse, Moro-Sibilot, Denis, Molinier, Olivier, Corre, Romain, Monnet, Isabelle, Gounant, Valérie, Langlais, Alexandra, Morin, Franck, Levallet, Guénaëlle, Zalcman, Gérard

“…Background The Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS/NCT00651456) phase 3 trial demonstrated the superiority of bevacizumab plus…”
Get full text

Lorlatinib: an additional option for ALK-positive non-small cell lung cancer? by Mogenet, Alice, Tomasini, Pascale, Greillier, Laurent, Barlesi, Fabrice

Get full text